CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 578 produtos para "CDK".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
(E/Z)-THZ1 2HCl
CAS:THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.Fórmula:C31H30Cl3N7O2Pureza:99.51%Cor e Forma:SolidPeso molecular:638.975BRD6989
CAS:BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.Fórmula:C16H16N4Pureza:99.43%Cor e Forma:SolidPeso molecular:264.325CDK2-IN-4
CAS:CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.Fórmula:C23H18N6O2SPureza:97.24% - 99.10%Cor e Forma:SolidPeso molecular:442.493XPW1
CAS:XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.Fórmula:C36H39ClFN7O2Pureza:99.63%Cor e Forma:White SolidPeso molecular:656.19GSK-3 inhibitor 4
CAS:Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.Fórmula:C22H15F2N5OPureza:99.82%Cor e Forma:SolidPeso molecular:403.38Samuraciclib hydrochloride
CAS:Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).Fórmula:C22H31ClN6OPureza:99.14% - 99.63%Cor e Forma:SolidPeso molecular:430.974Cirtuvivint
CAS:Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor that can be used to study arthritis.Fórmula:C24H25N7OPureza:99.95% - 99.96%Cor e Forma:Yellow SolidPeso molecular:427.5016Ca2+ channel agonist 1
CAS:Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.Fórmula:C19H26N6OPureza:97.71%Cor e Forma:SolidPeso molecular:354.4493CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Fórmula:C29H28FN5OCor e Forma:SolidPeso molecular:481.56EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Fórmula:C24H16N6OS2Pureza:98%Cor e Forma:SolidPeso molecular:468.55CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Fórmula:C18H18BrCl2N5O3Cor e Forma:SolidPeso molecular:503.177CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Cor e Forma:SolidPeso molecular:238.2845CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Fórmula:C15H16FN5Pureza:98%Cor e Forma:SolidPeso molecular:285.32PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Fórmula:C39H48Cl2N10O5Cor e Forma:SolidPeso molecular:807.768CDK2 degrader 7
CAS:CDK2 degrader7 is an orally active CDK2 degrader with DC50 values of 13 nM in MKN1 cells and 17 nM in TOV21G cells. It induces G1 phase arrest in MKN1 cells and achieves tumor suppression in the HCC1569 (CCNE1 amplified) xenograft model. CDK2 degrader7 is utilized in research on CCNE1 amplification-type cancers.Fórmula:C39H46F6N8O5SPeso molecular:852.9IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.6164BSJ-04-132
CAS:BSJ-04-132 is a Ribociclib-based PROTAC that selectively induces CDK4 degradation via CRBN recruitment, with no significant degradation of CDK6 or IKZF1/3.Fórmula:C42H49N11O7Cor e Forma:SolidPeso molecular:819.91CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Fórmula:C34H45N9O2Cor e Forma:SolidPeso molecular:611.795LO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Cor e Forma:Odour Solid
